What did the FDA decide on PFE's TUKYSA, trastuzumab, and pertuzumab?
The FDA decided PFE's (Pfizer Inc.) application for TUKYSA, trastuzumab, and pertuzumab on October 7, 2026: Approved. pdufa.bio does not hold a sponsor-disclosed goal date for this application. Verify against the linked primary source.
What is PFE's drug TUKYSA, trastuzumab, and pertuzumab?
TUKYSA, trastuzumab, and pertuzumab is Pfizer Inc.'s drug, approved by the FDA on October 7, 2026 for HER2+ Metastatic Breast Cancer.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move of 1.0% in either direction (898 large-cap decisions in our 1,886-decision run-up study, 2020-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up
Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.